Myriad Genetics
MYGN
196 hedge funds and large institutions have $508M invested in Myriad Genetics in 2026 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 75 increasing their positions, 59 reducing their positions, and 46 closing their positions.
106% more call options, than puts
Call options by funds: $261K | Put options by funds: $127K
27% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 59
0.01% more ownership
Funds ownership: 94.18% → 94.19% (+0.01%)
2% less capital invested
Capital invested by funds: $519M → $508M (-$11.4M)
7% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 46
3% less funds holding
Funds holding: 203 → 196 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$18.6M |
| 2 |
BlackRock
New York
|
+$9.08M |
| 3 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$6.97M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$4.91M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$3.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Glenview Capital Management
New York
|
-$24.4M |
| 2 |
HF
HRT Financial
New York
|
-$5.65M |
| 3 |
Jane Street
New York
|
-$5.41M |
| 4 |
Fisher Asset Management
Camas,
Washington
|
-$5.36M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.26M |
MYGN Hedge Fund Activity: Q2 2026 in Review
196 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q2 2026, worth a combined $508M — down 2.2% from $519M a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of MYGN and 43 opened new positions — a net loss of 3 holders — while 59 trimmed existing stakes and 75 added.
The largest buyer was Vestal Point Capital, adding an estimated $18.6M. The largest seller was Glenview Capital Management, exiting entirely with an estimated $24.4M sold.
- 196 institutional investors held Myriad Genetics (MYGN) as of Q2 2026, down from 203 in Q1 2026.
- Funds reported $508M of Myriad Genetics stock for Q2 2026, down 2.2% quarter-over-quarter.
- 43 funds opened new Myriad Genetics positions in Q2 2026 and 46 closed out, a net change of -3 holders.
- The largest Myriad Genetics buyer in Q2 2026 was Vestal Point Capital, an estimated $18.6M added.
- The largest Myriad Genetics seller in Q2 2026 was Glenview Capital Management, an estimated $24.4M sold.
Based on aggregated 13F filings for Q2 2026.